After several strong weeks in tech stocks like AMD, attention is now turning to a new opportunity in biotech — Viking Therapeutics (NASDAQ: VKTX).
Last week, we noted AMD’s sharp move from $167.76 in August to $263.35 today. That same kind of momentum may now be building in Viking Therapeutics.
🧬 Why Viking Therapeutics Is Heating Up
Analysts at Canaccord Genuity recently began coverage on VKTX with a buy rating and a price target of $106 per share. This shows growing confidence in the company’s leadership and long-term potential.
Viking’s main focus is on developing treatments for obesity, one of the fastest-growing markets in healthcare. Its lead product, VK2735, is now moving through Phase 3 clinical trials for an injectable obesity drug.
According to the company’s press release,
“Viking expects to complete enrollment in the VANQUISH-1 study by the end of 2025 and the VANQUISH-2 study in early 2026.”
This progress continues to build investor excitement.
💬 CEO Commentary and Pipeline Growth
Viking CEO Brian Lian, Ph.D. said the company is also preparing to launch another clinical study later this year. It will test a monthly maintenance version of VK2735.
He also confirmed that results from the Phase 2 oral dosing study are expected during the second half of this year.
“We continue to build on the encouraging early data from the oral tablet formulation of VK2735,” said Lian.
These updates reinforce confidence that Viking is moving steadily toward commercialization.
💰 Buyout Buzz and Market Speculation
Adding to the excitement, there are rumors that Pfizer (PFE) may be interested in acquiring Viking Therapeutics. Pfizer’s CEO, Albert Bourla, recently said the company is exploring new deals to expand its obesity treatment pipeline.
If such a partnership or acquisition happens, it could push VKTX shares much higher.
📈 Technical Outlook
VKTX last traded near $35.66 after a short consolidation period.
The next target is $42.23, which marks prior resistance.
If shares break above that level, a move toward $55 could follow.
Momentum indicators suggest buyers are stepping back in, and sentiment appears to be improving. As a result, VKTX may soon enter another strong uptrend.
🧠 Trading Insight from Ian Cooper
Ian Cooper — an experienced trader who blends technical, fundamental, and news-based analysis — continues to highlight stocks like VKTX through his Premium Options Strategies.
His proven approach helps traders identify setups early and manage risk with confidence.